Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm https://t.co/XCJ6coDpWI https://t.co/XCJ6coDpWI ...

Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm https://t.co/PlCpFbwxhb https://t.co/PlCpFbwxhb ...

I think I'm right in saying that in the context of robotics history, this was one of the top series Bees of All time. It's a significant sum of money. Let's start with what you're going to do with that funding and what you need to do to make progress.Right. Ed, first of all, thank you for having me. It's a pleasure to be here.What we're developing it for said, as you said, it's a robotic platform to tackle one of the biggest needs in medicine, which is the vision crisis. So currently today we have over 2 bi ...

Millions of people get cataract surgery every year. What if a robot could do it better than humans? https://t.co/hUI5HXteAl https://t.co/hUI5HXteAl ...

San Diego, CA, June 25, 2025 (GLOBE NEWSWIRE) -- Gordon Schanzlin New Vision Institute is proud to announce it is the first clinic in the United States to use both the Unity® Vision Centerpiece (Unity VCS™) and Unity® Cataract System (Unity CS™), the groundbreaking new phacoemulsification technology from Alcon. This state-of-the-art platform represents the most significant advancement in cataract surgery technology in over 15 years. Dr. Julio Echegoyen, cataract surgeon and ophthalmologist at Gordon Schanzl ...

Core Insights - RxSight, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $37.9 million, a 28% increase from $29.5 million in Q1 2024, driven by significant growth in Light Adjustable Lens (LAL) sales [4][9] - The company continues to emphasize the clinical value of its Light Adjustable Lens, which is gaining traction among cataract surgeons, and believes that customization and post-operative adjustability will be key trends in premium cataract surgery [3][9] Financial Performance - Total revenue for Q1 2025 was $37.9 million, up 28% from $29.5 million in Q1 2024, with LAL revenue increasing by 37% and Light Delivery Device (LDD) revenue rising by 8% [4][9] - Gross profit for Q1 2025 was $28.3 million, representing 74.8% of revenue, an increase from $20.7 million or 70.1% of revenue in Q1 2024, attributed to lower cost of sales and a favorable product mix [5][9] - Operating expenses for Q1 2025 totaled $39.0 million, a 24% increase from $31.4 million in Q1 2024, reflecting investments in LDD and R&D [6][9] - The net loss for Q1 2025 was $(8.2) million, or $(0.20) per share, an improvement from a net loss of $(9.1) million, or $(0.25) per share in Q1 2024 [7][9] Guidance and Market Position - The company reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, indicating growth of 14% to 25% compared to 2024 [10] - Gross margin is expected to be in the range of 71% to 73%, while operating expenses are projected to be between $150.0 million and $160.0 million, reflecting a 10% to 18% increase compared to 2024 [10][11] - RxSight sold 27,579 LALs in Q1 2025, a 36% increase in procedure volume compared to the same period in 2024, and expanded its installed base of LDDs to 1,044, a 43% increase year-over-year [9][10]

LENSAR, Inc. (NASDAQ:LNSR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this c ...